Superbug Solutions Platform is a concept to improve antibiotics (AB) which subsequently lost potency and their ability to eliminate antibiotic resistant bacteria (ABR-bacteria), including — microbes, resistant to ALL antibiotics (SUPER BUGS)

Superbug Solutions Platform simultaneously operates in two directions:

1

preventing development of ABR-bacteria

2

eliminating ABR-bacteria

Superbug Solutions Platform has 1000 potential safe antimicrobal drugs
(antibiotics with special additives, so called combined drugs)

AntiBiotics Combined Drugs,

including

84

combinations verified by experiments

19

combinations confirmed their effectiveness

10

combinations succeeded in overcoming ABR

Superbug Solutions Platform uses certain specific, thoroughly investigated, and safe natural compounds (i.e. substances widely occuring in nature) that are isolated from plants and bacteria.

History of Antibiotics:
discovery and their development

1

There were NO new AB developed in last 30 years

2

Existing AB are ineffective

3

In 2015, 8 million individuals died due to bacterial infections and/or resulting effects

1

NO new AB in last 30 years

2

Existing AB are ineffective

3

In 2015, 8 million individuals died due to bacterial infections and/or resulting effects

World Health Organization Mortality Data

10 global leading causes of death in 2015

Bacteria related death rate is 6 times higher than from motor and traffic related deaths

* bacterial and infectuous diseases

Global spread of ABR pathogenic bacteria and their effects per different regions

Mortality projections of ABR-related deaths by 2050 and its economic effects

Superbug Solutions Platform: Current Checklist Status

Conducting in vitro data verification and confirmation in independent laboratories under the supervision and management of Dr. Sergey Sidorenko in Federal State Organization Research Institute for childrens' infections, Federal Medical and Biological Agency of Russia

Conducting in vitro data verification and confirmation in independent laboratories under the supervision and management of Dr. Alexander Borizlov in Federal Budget Institution of Science «State Research Center for Applied Microbiology & Biotechnology» (FBIS SRCAMB) possessing GLP status and tare care animal protocol (TCAP)

Patent applications filed in Russian Federation and with PCT

Team formed and established for platform development, clinical trials, product registration and deployment into the market.

Attracting prospective investors and seeking external financing

In vitro data:

Minimal growth-inhibiting concentrations (MIC) decrease for various bacteria (both antibiotics sensitive and resistant, S/R) and different antibiotics with Superbug Solutions additive

Preventing further ABR development in ABCD application

ABR always occurs! ( it is the Law of Nature)

In vivo studies: mice lethally infected with Klebsiella pneumoniae, pathogen content in organs after 24 hours

K. pneumoniae KPM9 cell content in left thigh muscle tissue (left thigh), spleen and blood of mice infected intramuscularly with pathogen culture in 200 LD50 dose 24 hours after the beginning of two-time injection of Polymyxin B in 1.25 and 0.6 mg/kg doses in combination with M13. M13 and Polymyxin B were introduced into mice twice a day intragastrically and intraperitoneally in accordance with the experiment protocol. Treatment started 2 hours after infection. Mean values and standard deviations (n=6) are shown.

Conclusion: AntiBiotics Combined Drugs (ABCD) are more effective than pure antibiotic

1

with the same dose of antibiotics

2

with twice reduced dose of antibiotics

Mechanism of Superbug Solutions additive action: target 1 is membrane

Superbug Solutions additive modifies bacterial membranes (micro-viscosity increases); which causes respiration (and other membrane functions) inhibition (next slide). This weakens bacteria’s metabolism and defense mechanisms. This increases antibiotics’ efficiency.

Superbug Solutions additive analogue action on pyrene eximerization (PEx) velosity - the lower is PEx, the higher is membrane viscosity (arbitrary units, AU).

Scheme of bacterial membranes micro-viscosity increase in the presence of Superbug Solutions additive analogues

Mechanism of Superbug Solutions additive analogue action: target 1 is membrane

Respiration inhibition by Superbug Solutions additive analogue

Mechanism of Superbug Solutions additive analogues action: target 2 are proteins

Superbug Solutions additive analogue modifies bacterial proteins (enzymes and other)

Mechanism of Superbug Solutions additive analogues action: computer modeling of Superbug Solutions Platform additive analogue and proteins interaction

Lysozyme structure, modified by Superbug Solutions additive analogue as retrieved by computer modeling.
Download the scientific rationale

Contacts

SUPERBUG SOLUTIONS UK LTD

72 Great Suffolk Street, London, England, SE1 0BL

Scientific part

un@superbugsolutions.io

Common department

info@superbugsolutions.io